Answers are grounded in this paper and cite their sources.
Inflammation, particularly chronic inflammation, underlies the pathogenesis of numerous major diseases; therefore, anti-inflammatory therapy represents a highly promising strategy for their prevention and treatment. Owing to their multi-target activities, low toxicity, and remarkable chemical diversity, natural products exhibit immense potential in combating inflammation. Although they have garnered widespread attention in the treatment of inflammatory diseases due to their potent efficacy and favorable safety profiles, their clinical application remains largely restricted by inherent physicochemical limitations. To systematically address these challenges, this review reclassifies naturally derived pharmacologically active substances into three primary categories, comprehensively analyzing the specific bottlenecks each category encounters during clinical translation. Driven by these application demands, this article highlights the critical role of stimuli-responsive polymeric carriers in overcoming these limitations. By integrating principles from materials science and pharmaceutics, the review elaborates on how morphological strategies of polymeric matrices can be tailored to address the specific physicochemical deficits of these drugs, thereby facilitating precise targeted delivery to lesion sites. Furthermore, considering the increasing complexity of modern carrier design, this review prospectively introduces the concept of artificial intelligence (AI)-assisted design, discussing emerging applications of AI in accelerating natural product screening and the rational design of smart delivery systems. Ultimately, this review underscores that stimuli-responsive polymeric carriers can not only effectively circumvent the drawbacks of conventional drug administration but also significantly reduce required dosages and adverse side effects via precisely controlled release. Consequently, this work establishes a robust theoretical foundation and outlines novel developmental trajectories for next-generation therapeutic strategies against inflammatory diseases.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: